What Atmo Biosciences does

Atmo Biosciences is an Australian digital health company founded in 2017 that has developed the Atmo Gas Capsule System, an ingestible gas-sensing capsule used by gastroenterologists and hospitals to objectively assess gastrointestinal motility disorders. The capsule measures hydrogen, carbon dioxide, oxygen, temperature, capsule tumble and antenna reflectance in real time as it transits the GI tract; data is wirelessly transmitted to a cloud platform that derives whole and regional gut transit times (stomach, small bowel, colon) and produces reports used to identify gastroparesis and slow transit constipation. The company received US FDA 510(k) clearance for the system in June 2025 and commercially launched in the United States from July 2025, with a second FDA clearance (Contractility Frequency Map feature) issued in May 2026.

The capsule technology originated in research at RMIT University; in April 2025 Atmo completed full assignment of the foundational patent portfolio covering granted patents in the US, EU, Australia and Japan with coverage to 2037, consolidating the IP base ahead of US commercialisation. The clinical evidence stack comprises approximately 12 studies covering more than 570 ingested capsules, supported by a Medical Advisory Board chaired by Prof. Eamonn Quigley with principal investigators at Harvard/Massachusetts General Hospital, University of Michigan, and other US academic centres. Manufacturing is performed by Planet Innovation in Melbourne under ISO 13485:2016 certification, providing a contract-manufacturing backbone for scaled capsule production.

Atmo monetises by selling the capsule system to healthcare providers (gastroenterology practices and hospitals) on a B2B enterprise field-sales basis, with reimbursement supported by existing CPT codes and an Otsuka-led Series B signalling intended strategic alignment for gastrointestinal-focused commercialisation. Cumulative disclosed equity funding totals approximately A$23.6M across a 2018 seed (A$2.5M from Planet Innovation), a 2021 Series A (A$9.6M from Alium Capital and Otsuka) and a 2023 Series B (A$8M led by Otsuka Holdings), supplemented by Australian federal and state grants and undisclosed investment from Breakthrough Victoria and the ANDHealth+ program. The company has a US presence in Eden Prairie, Minnesota and previously operated from JLABS @ San Diego, and is preparing for a Series C round to fund US commercialisation and manufacturing scale-up.

Name

Atmo Biosciences

Legal name

Atmo Biosciences Limited

Website

https://atmobiosciences.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Atmo Biosciences is an Australian digital health company that develops and commercializes the Atmo Gas Capsule System, an ingestible gas-sensing capsule that gastroenterologists and hospitals use to objectively assess gastrointestinal motility disorders including gastroparesis and slow transit constipation.

Ownership category

akta.pro rank

Product category

Gastrointestinal Diagnostic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

General Gastroenterology (HLAKAEAA)

Keywords

• Ingestible gas-sensing capsule
• Gastrointestinal motility diagnostics
• Digital health medical device
• Gut transit measurement
• Wireless motility capsule

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Atmo Gas Capsule System: Sale of ingestible gas-sensing capsule medical device for gastrointestinal motility assessment. The company received FDA 510(k) clearance in June 2025 for the initial indication to aid diagnosis of dysmotility disorders, with commercial launch in the USA from July 2025. Revenue generated from hardware sales of the capsule system to healthcare providers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Atmo Biosciences develops and commercializes the Atmo Gas Capsule System, an ingestible gas-sensing capsule that measures gases (hydrogen, carbon dioxide, oxygen) directly at the source of production in the gastrointestinal tract. The capsule uses onboard sensors (temperature, gas, capsule tumble, antenna reflectance) to determine its location and measures whole gut and regional gut (stomach, small bowel, and colon) transit times. Data is wirelessly transmitted to a cloud-based platform for aggregation, analysis, and patient reporting, aiding gastroenterologists in diagnosing motility disorders such as gastroparesis and slow transit constipation.

Product overview

Atmo Biosciences offers a single unified product, the Atmo Gas Capsule System, consisting of an ingestible gas-sensing capsule and cloud-connected data analysis platform. The core Atmo Gas Capsule is a swallowable device that measures gases (hydrogen, carbon dioxide, oxygen) at source in the GI tract and transmits data wirelessly to the cloud. The Contractility Frequency Map is a feature enhancement that provides visual mapping of GI contractile activity. The system aids gastroenterologists in diagnosing motility disorders such as gastroparesis and slow transit constipation by measuring whole and regional gut transit times.

Differentiator

Problem solved

Functional benefit

Products and services

• Atmo Gas Capsule System An ingestible gas-sensing capsule system for healthcare providers and gastroenterologists. It measures whole gut and regional gut (stomach, small bowel, colon) transit times using onboard sensors (temperature, hydrogen concentration, carbon dioxide concentration, oxygen level, capsule tumble, antenna reflectance) and transmits data wirelessly to a cloud-based platform for aggregation, analysis, and patient reporting to aid diagnosis of motility disorders such as gastroparesis and slow transit constipation.

Quantifiable outcome

• 3,000 times more accurate than breath tests in detecting gas biomarkers
• +3 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Six partnerships are on record, tiered supporting, key and core.

• ANDHealth+supportingOthers · 14 October 2024Digital health commercialization program providing up to A$3.75 million in non-dilutive funding and hands-on support. Atmo was selected for Stage 2 funding as one of five digital health companies in the program.
• ps.healthcaresupportingTechnology or Integration · 26 October 2023Partnership to shape Atmo's data strategy and create a roadmap of future applications using machine learning (ML) and artificial intelligence (AI) capabilities.
• Johnson & Johnson Innovation - JLABSsupportingStrategic or Co-development Partner · 17 April 2023Atmo Biosciences became a resident company of JLABS @ San Diego, a premier life science incubator providing access to collaboration opportunities with other life science companies focused on microbiome, precision medicine, and therapeutic solutions.
• Seed HealthkeyStrategic or Co-development Partner · 1 November 2019Research partnership to evaluate impact of probiotics on gut microbiome using the Atmo Gas Capsule in clinical trials. First study evaluates effects of antibiotics on the GI tract and probiotic intervention.
• RMIT UniversitycoreTechnology or Integration · 1 January 2018Original technology licensing deal in 2018 securing exclusive worldwide rights to commercialize the ingestible gas-sensing capsule technology developed at RMIT. In April 2025, RMIT transferred all patents and associated IP to Atmo in exchange for an equity stake, strengthening the long-term collaboration.
• Planet InnovationcoreStrategic or Co-development PartnerHealthtech commercialization company that incubated Atmo Biosciences and continues as manufacturing partner, producing the Atmo Gas Capsule at their ISO 13485:2016 certified medtech manufacturing facility in Melbourne.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Given Imaging (now Medtronic): Given Imaging pioneered PillCam capsule endoscopy and is now part of Medtronic. It remains the historical category-defining peer for ingestible GI capsule diagnostics.
• Medtronic (SmartPill): Medtronic commercializes the SmartPill wireless motility capsule, which is the FDA-cleared predicate device used in Atmo's pivotal clinical study. It is the most direct comparator for ingestible capsule-based GI motility assessment.
• AnX Robotica (Navicam): AnX Robotica develops Navicam, a magnetically controlled capsule endoscopy system for GI examination. It is a direct peer in the ingestible capsule diagnostic space targeting gastroenterologists and hospitals.
• CapsoVision: CapsoVision makes the CapsoCam Plus, a small-bowel capsule endoscope that competes with other ingestible GI capsules. It is comparable to Atmo as a developer of swallowable GI diagnostic devices serving gastroenterology practices.
• IntroMedic (MiroCam): IntroMedic manufactures the MiroCam capsule endoscopy system, another ingestible GI capsule product. Comparable to Atmo as a capsule-based diagnostic device sold into gastroenterology workflows globally.

Broad incumbents

• Olympus (Endocapsule): Olympus sells the Endocapsule system, an ingestible capsule endoscope used in GI visualization. While its primary use case differs (imaging vs. gas sensing), it is a broad incumbent in the ingestible GI capsule category.
• Pentax Medical (capsule endoscopy): Pentax Medical, part of HOYA, sells ingestible capsule endoscopy systems serving gastroenterologists. It is a broad incumbent offering capsule-based GI diagnostics with overlapping clinician customer base.
• Hologic: Hologic is a large diagnostics and medical device company that includes GI-related diagnostics and women's health franchises. It is a broad incumbent in the diagnostic device category Atmo is entering.

Emerging players

• Check-Cap: Check-Cap is developing an ingestible X-ray-based capsule for colorectal cancer screening. While its clinical focus is CRC screening rather than motility, it competes in the regulatory and clinical pathway for ingestible diagnostic capsules.
• Vibrant: Vibrant develops an FDA-cleared, drug-free, disposable capsule for chronic constipation. It overlaps with Atmo's motility/slow transit constipation use case and competes for gastroenterologist mindshare.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/atmo-biosciences
• Xx.com/atmobio

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atmo Biosciences